Journal ArticleDOI
How to Diagnose and Treat a Cancer of Unknown Primary Site.
Ciprian Tomuleasa,Florin Zaharie,Mihai-Stefan Muresan,Laura Pop,Zsolt Fekete,Delia Dima,Ioana Frinc,Adrian P. Trifa,Cristian Berce,Ancuta Jurj,Ioana Berindan-Neagoe,Mihnea Zdrenghea +11 more
TLDR
Both the diagnostic challenges for patients with a cancer of unknown primary site as well as the current available therapeutic options are summarized, with emphasis on the management of this unique disease entity.Abstract:
Almost one in every three patients with advanced tumors have distant metastasis at the time of clinical diagnosis. In most cases, the primary tumor site is identified immediately, within a few days. But for some patients, the primary lesion cannot be found after the initial clinical assessment. These cases are called cancers of unknown primary origin (CUPs), a clinical diagnosis very difficult to manage by physicians due to the absence of a standard-of-care for the initial therapeutic regimen, as well as due to the impossibility to include these cases in randomized clinical trials. A cancer of unknown primary site is often associated with a poor prognosis as patients are usually treated with a non-selective empirical therapy. In the current paper, we summarize both the diagnostic challenges for patients with a cancer of unknown primary site as well as the current available therapeutic options, with emphasis on the management of this unique disease entity.read more
Citations
More filters
Journal ArticleDOI
Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site.
TL;DR: In comprehensive genomic profiling, it is observed that there is at least one clinically appropriate genomic alteration in CUP that can influence the targeted therapy and the targeted therapeutic approach will not only improve the disease outcome but will also be cost-effective and save time from finding the primary site.
Journal ArticleDOI
Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.
Ancuta Jurj,Laura Pop,Bobe Petrushev,Sergiu Pasca,Delia Dima,Ioana Frinc,Dalma Deak,Minodora Desmirean,Adrian P. Trifa,Bogdan Fetica,Grigore Gafencu,Sonia Selicean,Vlad Moisoiu,Wilhelm-Thomas Micu,Cristian Berce,Alexandra Sacu,Alin Moldovan,Andrei Colita,Horia Bumbea,Alina Tanase,Angela Dascalescu,Mihnea Zdrenghea,Rares Stiufiuc,Nicolae Leopold,Romulus Tetean,Emil Burzo,Ciprian Tomuleasa,Ioana Berindan-Neagoe +27 more
TL;DR: This project aimed to identify a microRNA species that can predict the evolution of therapy-resistant CLL towards RS, and identified microRNA-19b as a possible target and the mechanism by which miR-19B acts as the upregulation of Ki67 and downregulation of p53.
Journal ArticleDOI
Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets
Annie Schmid-Alliana,Heidy Schmid-Antomarchi,Rasha Al-Sahlanee,Patricia Lagadec,Jean-Claude Scimeca,Elise Verron +5 more
TL;DR: The gene expression profile of bone-seeking cancer cells is reported on and the cross-talk between the bone microenvironment and invading cells, which impacts on the tumour actions on surrounding bone tissue is discussed.
Journal ArticleDOI
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.
Antonella Argentiero,Antonio Giovanni Solimando,Oronzo Brunetti,Angela Calabrese,Francesco Pantano,Michele Iuliani,Daniele Santini,Nicola Silvestris,Angelo Vacca +8 more
TL;DR: It is pointed out that greater efforts are required to face the unmet needs present in SMUP patients in oncology.
Journal Article
Treatment of patients with cancer of an unknown primary site
Tomohiro Enokida,Yu Ohyama +1 more
TL;DR: Cancer of unknown primary (CUP) is a heterogenous group of tumors that accounts for 3 to 5 percent of all malignancies, and specific molecular markers and targeted therapy are being explored.
References
More filters
Journal ArticleDOI
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery,Jean Paul Thiery,Hervé Acloque,Ruby Yun-Ju Huang,Ruby Yun-Ju Huang,M. Angela Nieto +5 more
TL;DR: The mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.
Journal ArticleDOI
Dissemination and growth of cancer cells in metastatic sites
TL;DR: Inhibition of the growth of metastases in secondary sites offers a promising approach for cancer therapy and could help to improve the treatment of metastatic disease.
Journal ArticleDOI
Microenvironmental regulation of metastasis
TL;DR: Experimental data demonstrating the role of the microenvironment in metastasis is described, areas for future research are identified and possible new therapeutic avenues are suggested.
Journal ArticleDOI
Tumor Metastasis: Molecular Insights and Evolving Paradigms
TL;DR: The invasion-metastasis cascade is a multistep cell-biological process that involves dissemination of cancer cells to anatomically distant organ sites and their subsequent adaptation to foreign tissue microenvironments as mentioned in this paper.
Journal ArticleDOI
Tumour-cell invasion and migration: diversity and escape mechanisms
Peter Friedl,Katarina Wolf +1 more
TL;DR: Cancer cells possess a broad spectrum of migration and invasion mechanisms and learning more about the cellular and molecular basis of these different migration/invasion programmes will help to understand how cancer cells disseminate and lead to new treatment strategies.